![ISPOR Europe 2024 – May 5-8. Register now.]({"type":"image" , "src" : "/sda/112342/JournalAd-ISPOR-2024-Leaderboard.jpg"})
Citations (32)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Yuyao Sun, Michael Benatar, Javier Mascías Cadavid, Dave Ennist, Paul Wicks, Kim Staats, Morgan Beauchamp, Sartaj Jhooty, Gary Pattee, Andrew Brown, Tulio Bertorini, Paul Barkhaus, Mark Bromberg, Greg Carter, Richard Bedlack & Xiaoyan Li. (2023) ALSUntangled #71: Nuedexta. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 0:0, pages 1-5.
Read now
Read now
David G Coughlin & Irene Litvan. (2022) Investigational therapeutics for the treatment of progressive supranuclear palsy. Expert Opinion on Investigational Drugs 31:8, pages 813-823.
Read now
Read now
Marian W. Roman. (2015) NueDexta: A Treatment for Pseudobulbar Affect. Issues in Mental Health Nursing 36:12, pages 1019-1021.
Read now
Read now
Articles from other publishers (29)
Naser-Aldin Lashgari, Maryam Shayan, Hedieh shamsnia, Nazanin Momeni Roudsari, Saeideh Momtaz & Amir Hossein Abdolghaffari. 2024. Encyclopedia of Toxicology. Encyclopedia of Toxicology
91
102
.
Elliot W. McClure & R. Nathan Daniels. (2023) Classics in Chemical Neuroscience: Dextromethorphan (DXM). ACS Chemical Neuroscience 14:12, pages 2256-2270.
Crossref
Crossref
Emma Husbands & Kevin Talbot. (2022) Pathological laughter and crying in neurological disorders: recognition and treatment. Practical Neurology 22:6, pages 486-490.
Crossref
Crossref
Michael Francis, Mira Hamame, Mariam Nasrallah, Alison Nesbitt & James P. Meza. (2021) Dextromethorphan-quinidine is helpful for pseudobulbar affect disorder in stroke patients. Clinical Research In Practice: The Journal of Team Hippocrates 7:2.
Crossref
Crossref
Jesus Sancho, Santos Ferrer, Enric Burés, José Luis Díaz, Teresa Torrecilla, Jaime Signes-Costa & Emilio Servera. (2021) Effect of one-year dextromethorphan/quinidine treatment on management of respiratory impairment in amyotrophic lateral sclerosis. Respiratory Medicine 186, pages 106536.
Crossref
Crossref
Hendrik Lintel, Timothy Corpuz, Saif-ur-Rahman Paracha & George T. Grossberg. (2021) Mood Disorders and Anxiety in Parkinson’s Disease: Current Concepts. Journal of Geriatric Psychiatry and Neurology 34:4, pages 280-288.
Crossref
Crossref
David G. Coughlin, Dennis W. Dickson, Keith A. Josephs & Irene Litvan. 2021. Frontotemporal Dementias. Frontotemporal Dementias
151
176
.
Nicholas E. Karagas, Natalia Pessoa Rocha & Erin Furr Stimming. (2020) Irritability in Huntington’s Disease. Journal of Huntington's Disease 9:2, pages 107-113.
Crossref
Crossref
Michael Chez, Shawn Kile, Christopher Lepage, Carol Parise, Bobbie Benabides & Andrea Hankins. (2018) A Randomized, Placebo-Controlled, Blinded, Crossover, Pilot Study of the Effects of Dextromethorphan/Quinidine for the Treatment of Neurobehavioral Symptoms in Adults with Autism. Journal of Autism and Developmental Disorders 50:5, pages 1532-1538.
Crossref
Crossref
David G. Coughlin & Irene Litvan. (2020) Progressive supranuclear palsy: Advances in diagnosis and management. Parkinsonism & Related Disorders 73, pages 105-116.
Crossref
Crossref
Amelia J. Hicks, Fiona J. Clay, Jennie L. Ponsford, Luke A. Perry, Mahesh Jayaram, Rachel Batty & Malcolm Hopwood. (2020) Pharmacotherapy for the Pseudobulbar Affect in Individuals Who Have Sustained a Traumatic Brain Injury: a Systematic Review. Neuropsychology Review 30:1, pages 28-50.
Crossref
Crossref
Mathew Hakimi & Carine W. Maurer. (2019) Pseudobulbar Affect in Parkinsonian Disorders: A Review. Journal of Movement Disorders 12:1, pages 14-21.
Crossref
Crossref
Richard D. ZorowitzDavid N. Alexander, Andrea E. Formella, Fred Ledon, Charles Davis & Joao Siffert. (2019) Dextromethorphan/Quinidine for Pseudobulbar Affect Following Stroke: Safety and Effectiveness in the PRISM II Trial. PM&R 11:1, pages 17-24.
Crossref
Crossref
Linda Nguyen & Rae R. Matsumoto. 2019. Psychopharmacology of Neurologic Disease. Psychopharmacology of Neurologic Disease
243
251
.
Flora M. Hammond, William Sauve, Fred Ledon, Charles Davis & Andrea E. Formella. (2018) Safety, Tolerability, and Effectiveness of Dextromethorphan/Quinidine for Pseudobulbar Affect Among Study Participants With Traumatic Brain Injury: Results From the PRISM-II Open Label Study. PM&R 10:10, pages 993-1003.
Crossref
Crossref
Fiona J. Clay, Amelia J. Hicks, Luke A. Perry, Jennie L. Ponsford, Mahesh Jayaram & Malcolm Hopwood. (2018) Pharmacotherapy for the pseudobulbar affect in individuals who have sustained a traumatic brain injury: a systematic review protocol. JBI Database of Systematic Reviews and Implementation Reports 16:9, pages 1739-1757.
Crossref
Crossref
Natalia Ospina-García, Gustavo C Román, Belén Pascual, Mary R Schwartz & Hector Alejandro Preti. (2018) Hypothalamic relapse of a cardiac large B-cell lymphoma presenting with memory loss, confabulation, alexia–agraphia, apathy, hypersomnia, appetite disturbances and diabetes insipidus. BMJ Case Reports, pages bcr-2016-217700.
Crossref
Crossref
Frank A. Rodden. (2018) The neurology and psychiatry of humor, smiling and laughter: A tribute to Paul McGhee. Part I. Introduction and clinical studies. HUMOR 31:2, pages 339-371.
Crossref
Crossref
Abhijit Dey & Anuradha Mukherjee. 2018. Discovery and Development of Neuroprotective Agents from Natural Products. Discovery and Development of Neuroprotective Agents from Natural Products
237
320
.
Frank Rodden. (2017) The neurology and psychiatry of humor, smiling and laughter: A tribute to Paul McGhee. Part I. Introduction and clinical studies. HUMOR 0:0.
Crossref
Crossref
Richard Smith, Erik Pioro, Kathleen Myers, Michael Sirdofsky, Kimberly Goslin, Gregg Meekins, Hong Yu, James Wymer, Merit Cudkowicz, Eric A. Macklin, David Schoenfeld & Gary Pattee. (2017) Enhanced Bulbar Function in Amyotrophic Lateral Sclerosis: The Nuedexta Treatment Trial. Neurotherapeutics 14:3, pages 762-772.
Crossref
Crossref
Robert G. WahlerJrJrAlfred T. ReimanJoshua V. Schrader. (2017) Use of Compounded Dextromethorphan–Quinidine Suspension for Pseudobulbar Affect in Hospice Patients. Journal of Palliative Medicine 20:3, pages 294-297.
Crossref
Crossref
Ji-ye Liu & Ying-hua Chen. (2017) Influence of acupoint-injection on TXB2 and 6-keto-PGF1a in patients with pseudobulbar palsy: a randomized controlled trial穴位注射对假性延髓麻痹患者TXB2 和6-keto-PGF1a 的影响的随机对照试验. Journal of Acupuncture and Tuina Science 15:1, pages 22-26.
Crossref
Crossref
M. Cataldi. 2017. Reference Module in Biomedical Sciences. Reference Module in Biomedical Sciences.
Flora M. Hammond, David N. Alexander, Andrew J. Cutler, Stephen D’Amico, Rachelle S. Doody, William Sauve, Richard D. Zorowitz, Charles S. Davis, Paul Shin, Fred Ledon, Charles Yonan, Andrea E. Formella & Joao Siffert. (2016) PRISM II: an open-label study to assess effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injury. BMC Neurology 16:1.
Crossref
Crossref
Rachelle S. Doody, Stephen D’Amico, Andrew J. Cutler, Charles S. Davis, Paul Shin, Fred Ledon, Charles Yonan & João Siffert. (2015) An open-label study to assess safety, tolerability, and effectiveness of dextromethorphan/quinidine for pseudobulbar affect in dementia: PRISM II results. CNS Spectrums 21:6, pages 450-459.
Crossref
Crossref
Linda Nguyen, Kelan L. Thomas, Brandon P. Lucke-Wold, John Z. Cavendish, Molly S. Crowe & Rae R. Matsumoto. (2016) Dextromethorphan: An update on its utility for neurological and neuropsychiatric disorders. Pharmacology & Therapeutics 159, pages 1-22.
Crossref
Crossref
Eman Bahrani, Chloe E. Nunneley, Sylvia Hsu & Joseph S. Kass. (2016) Cutaneous Adverse Effects of Neurologic Medications. CNS Drugs 30:3, pages 245-267.
Crossref
Crossref
Lily P. H. Yang & Emma D. Deeks. (2014) Dextromethorphan/Quinidine: A Review of Its Use in Adults with Pseudobulbar Affect. Drugs 75:1, pages 83-90.
Crossref
Crossref